Rupert Vessey

Dr. Vessey is a member of Arsenal’s Healthcare Advisory Board. Currently, he is the Chief Scientist and Executive Partner of Flagship Pioneering. Previously, he served as Executive Vice President and President, Research for Bristol Myers Squibb (“BMS”) where he oversaw the advancement of promising programs, technologies, and assets across all therapeutic areas, from discovery through proof-of-concept. Dr. Vessey joined BMS from Celgene, where he served as the President of the company’s Research and Early Development organization. Prior to joining Celgene, he spent ten years at Merck, where he was responsible for numerous drug development programs and held leadership roles in the company’s Early Development, Discovery Sciences, Drug Discovery and Informatics groups, as well as its respiratory and immunology franchise. Prior to his time at Merck, he spent five years at GlaxoSmithKline involved in drug discovery, experimental medicine and early clinical development of therapeutics for respiratory and immune diseases.